Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.20 -0.14 (-0.78%)

Delayed Quote Updated: 10:19 AM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Wednesday's session: gap up and gap down stocks ↗

April 30, 2025

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Starbucks Posts Weak Earnings, Joins Super Micro Computer, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

April 30, 2025

Via Benzinga

Bausch + Lomb (NYSE:BLCO) Misses Q1 Sales Targets, Stock Drops 10.4%

April 30, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue...

Via StockStory

Earnings Scheduled For April 30, 2025 ↗

April 30, 2025

Via Benzinga

Earnings Scheduled For February 19, 2025 ↗

February 19, 2025

Via Benzinga

Bausch + Lomb Announces First-Quarter 2025 Results

April 30, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings

April 29, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know.

Via StockStory

Topics World Trade

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

April 28, 2025

Via Benzinga

Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall

April 24, 2025

From Bausch + Lomb Corporation

Via Business Wire

3 Reasons to Sell BLCO and 1 Stock to Buy Instead

April 18, 2025

Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 per share. This might have investors contemplating their next move.

Via StockStory

Topics Bankruptcy

3 of Wall Street’s Favorite Stocks in the Doghouse

April 16, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Topics Firearms

Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment

April 07, 2025

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers.

Via StockStory

Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks

April 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and...

Via StockStory

Why Bausch + Lomb (BLCO) Shares Are Plunging Today

March 28, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the "voluntary...

Via StockStory

Topics Artificial Intelligence Initial Public Offering

Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday ↗

March 28, 2025

Via Benzinga

Why Bausch + Lomb (BLCO) Stock Is Nosediving

March 27, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall was...

Via StockStory

Topics Artificial Intelligence Initial Public Offering

Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses

March 27, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

March 26, 2025

From Bausch + Lomb Corporation

Via Business Wire

3 Healthcare Stocks in the Doghouse

March 25, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States

March 17, 2025

From Bausch + Lomb Corporation

Via Business Wire

Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers

March 11, 2025

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.

Via StockStory

3 Stocks Under $50 Walking a Fine Line

February 28, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises ↗

February 19, 2025

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

Via Stocktwits

Topics Earnings

Globus Medical (GMED) Q4 Earnings: What To Expect

February 19, 2025

Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect.

Via StockStory

Earnings To Watch: Integer Holdings (ITGR) Reports Q4 Results Tomorrow

February 19, 2025

Medical technology company Integer Holdings (NYSE:ITGR) will be announcing earnings results tomorrow before market hours. Here’s what you need to know.

Via StockStory

Bausch + Lomb’s (NYSE:BLCO) Q4: Beats On Revenue

February 19, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year...

Via StockStory

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

February 19, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

February 18, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect.

Via StockStory

Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million ↗

February 07, 2025

Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.

Via Benzinga

Bausch + Lomb Provides Update on Potential Sale

February 06, 2025

From Bausch + Lomb Corporation

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.